Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2007-10-02
2007-10-02
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C514S012200
Reexamination Certificate
active
10115192
ABSTRACT:
A novel receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.
REFERENCES:
patent: 5969102 (1999-10-01), Bram et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6316222 (2001-11-01), Bram et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6475987 (2002-11-01), Shu
patent: 6541224 (2003-04-01), Yu et al.
patent: 6774106 (2004-08-01), Theill et al.
patent: 2002/0037852 (2002-03-01), Browning et al.
patent: 2002/0086018 (2002-07-01), Theill et al.
patent: 2002/0165156 (2002-11-01), Browning et al.
patent: 2002/0172674 (2002-11-01), Browning et al.
patent: 2003/0023038 (2003-01-01), Rennert et al.
patent: 2004/0013674 (2004-01-01), Ambrose et al.
patent: 2004/0072188 (2004-04-01), Ambrose et al.
patent: 2006/0067933 (2006-03-01), Gross et al.
patent: 0 869 180 (1998-10-01), None
patent: WO97/33902 (1997-09-01), None
patent: WO98/18921 (1998-05-01), None
patent: WO98/27114 (1998-06-01), None
patent: WO98/55620 (1998-12-01), None
patent: WO98/55621 (1998-12-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/12964 (1999-03-01), None
patent: WO99/12965 (1999-03-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO 00/26244 (2000-05-01), None
patent: WO 00/39295 (2000-07-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/43032 (2000-07-01), None
patent: WO 00/50597 (2000-08-01), None
patent: WO 00/50633 (2000-08-01), None
patent: WO 00/58362 (2000-10-01), None
patent: WO 00/68378 (2000-11-01), None
patent: WO 01/12812 (2001-02-01), None
patent: WO 01/087977 (2001-11-01), None
patent: WO 01/087979 (2001-11-01), None
patent: WO 02/02641 (2002-01-01), None
patent: WO 02/18620 (2002-03-01), None
patent: WO 03/055979 (2003-07-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Hane et al. (1998), APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth, J. Exp. Med. vol. 11, No. 6, pp. 1185-1190.
Bork, A. Powers and pitfalls in sequence aalysis: the 70% hurdle, (2000), Genome Res. 10: pp. 398-400.
Skolnick et al. From genes to protein structure and function: novel applications of computational approches in the genomic era, (2000), Trends in Biotech. 18(1): pp. 34-39.
Doerks et al. Protein annotation: detective work for function prediction, (1998), Trends in Genetics. 14(6): pp. 248-250.
Smith et al. the challenges of genome sequence annotation or “The devil is in the details”, (1997), Nature Biotech 15: pp. 1222-1223.
Brenner, S.E. Errors in genome function (1999), Trends in Genetics 15(40: pp. 132-133.
Bork et al. go hunting in sequence databases but watch out for traps (1996), Trends in Genetics 12(10): pp. 425-427.
Gras et al., “BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes”, International Immunology, vol. 7, No. 7, 1995, pp. 1093-1106.
Gross et al., “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease”, Nature, vol. 404, Apr. 27, 2000, pp. 995-999.
Hahne et al., “APRIL, A New Ligand of the Tumor Necrosis Factor Family. Stimulates Tumor Cell Growth”, J. Exp. Med., vol. 188. No. 6, Sep. 21, 1998, pp. 1185-1190.
Khare et al., “Severe B Cell Hyperplasia and Autoimmune Disease in TALL-1 Transgenic Mice”, Proceedings of the National Academy of Sciences of the United States of America. Mar. 28, 2000, vol. 97, No. 7, pp. 3370-3375.
Kwon et al.. “Functions of Newly Identified Members of theTumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes”, Current Opinion in Immunology. 1999, pp. 340-345.
Laabi et al., “A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4:16) (q26:p13) Translocation in a Malignant T Cell Lymphoma”, The EMBO Journal, vol. 11. No. 11, 1992, pp. 3897-3904.
Laabi et al., “The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, is Bidirectionally Transcribed”, Nucleic Acids Research, vol. 22, No. 7, 1994, pp. 1147-1154.
Mackay et al., “Mice Transgenic for BAFF Develop Lymphocytic Disorders along with Autoimmune Manifestations”, Journal of Experimental Medicine, Dec. 6, 1999, vol. 190, No. 11, pp. 1697-1710.
Maldry et al., “The Characterization of Murine BCMA Gene Defines it as a New Memer of the Tumor Necrosis Factor Receptor Superfamily”, International Immunology, vol. 10, No. 11, 1998, pp. 1693-1702.
Mukhopadhyay et al., “Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue that Activates Apoptosis, Nuclear Factor-kappaB, and c-Jun NH2-Terminal Kinase”, Journal of Biological Chemistry, Jun. 4, 1999, vol. 274, No. 23, pp. 15978-15981.
Moore et al., “BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator”, Science. Jul. 9, 1999, vol. 285, No. 5425, pp. 260-263.
Pitti et al., “Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer”, Nature. vol. 396. Dec. 17, 1998, pp. 699-703.
Schneider et al., “BAFF, A Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth”, J. Exp. Med., vol. 189, No. 11, Jun. 7, 1999, pp. 1747-1756.
Shu et al., “B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1”, PNAS. vol. 97, No. 16, Aug. 1, 2000. pp. 9156-9161.
Thompson et al., “BAFF Interacts with the Orphan Receptor, BCMA”, Scandinavian Journal of Immunology. vol. 51 (Supplement 1), 2000. p. 65.
Thompson et al., “BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population”, J. Exp. Med., vol. 192. No. 1, Jul. 3, 2000. pp. 129-135.
Xia et al., “TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation”, J. Exp. Med., vol. 192, No. 1, Jul. 3, 2000, pp. 137-143.
Yu et al., “APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity”, Nature Immunology, vol. 1, No. 3, Sep. 2000, pp. 252-256.
Kashii, Y. et al., “Constitutive Expression and Role of the TNF Family Ligands in Apoptotic Killing of Tumor Cells by Human NK Cells,”J. Immunol. 163:5358-66. (1999).
Ward, P. and Mulligan, M. “Blocking of Adhesion Molecules in vivo as Anti-Imflammatory Therapy,”Ther. Immunol. 1:165-71 (1994).
Ware, C., “APRIL and BAFF Connect Autoimmunity and Cancer,”J. Exp. Med. 192:F35-F37 (2000).
von Bulow & Bram, “NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily,”Science 278:138-141 (1997).
Ambrose Christine
Cachero Teresa
Rennert Paul
Schneider Pascal
Thompson Jeffrey
Apoxis SA
Biogen Idec MA Inc.
Finnegan Henderson Farabow Garrett & Dunner LLP
Saoud Christine J.
Seharaseyon Jegatheesan
LandOfFree
Methods of treating a tumor that expresses APRIL by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating a tumor that expresses APRIL by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating a tumor that expresses APRIL by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864257